The rise of Viagra initially sparked a period of growth for pharma, but recent developments present a uncertain scenario for those considering a stake. Generic competitors are eroding earnings, and persistent legal battles add further risk to the landscape. While certain companies might still gain from related products, the broader trend suggests a